GLPG VS IRTC Stock Comparison

Performance

GLPG
75/100

GLPG returned -9.92% in the last 12 months. Based on SPY's performance of -13.22%, its performance is above average giving it a score of 74 of 100.

IRTC
10/100

IRTC returned -23.59% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

GLPG
78/100

8 analysts offer 12-month price targets for GLPG. Together, they have an average target of 88.89, the most optimistic target put GLPG at 97 within 12-months and the most pessimistic has GLPG at 83.74.

IRTC
75/100

4 analysts offer 12-month price targets for IRTC. Together, they have an average target of 158.88, the most optimistic target put IRTC at 198 within 12-months and the most pessimistic has IRTC at 110.

Technicals

GLPG
71/100

GLPG receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.

IRTC
50/100

IRTC receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

GLPG
10/100

GLPG has missed earnings 10 times in the last 20 quarters.

IRTC
10/100

IRTC has missed earnings 8 times in the last 20 quarters.

Profit

GLPG
40/100

Out of the last 20 quarters, GLPG has had 8 profitable quarters and has increased their profits year over year on 6 of them.

IRTC
10/100

Out of the last 20 quarters, IRTC has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

GLPG
50/100

GLPG has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

IRTC
45/100

IRTC has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Galapagos NV Summary

Nasdaq / GLPG

Healthcare

Biotechnology

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

iRhythm Technologies, Inc Summary

Nasdaq / IRTC

Healthcare

Medical - Devices

iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Power up your portfolio